Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monother...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet oncology Ročník 22; číslo 6; s. 848 - 857
Hlavní autoři:	Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, Fury, Matthew G
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.06.2021 Elsevier Limited Elsevier
Témata:	Adverse events Basal cell carcinoma Cancer Colitis FDA approval Hematology, Oncology, and Palliative Medicine Immunotherapy Intolerance Life Sciences Lung cancer Metastases Metastasis Monoclonal antibodies Non-small cell lung carcinoma Patients PD-1 protein Photography Radiation therapy Radiology Skin cancer Squamous cell carcinoma Statistical analysis Surgery Targeted cancer therapy Toxicity Tumors United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!